Press releases

Month Year

Email alerts

Nov 3, 2015

HeartWare International Announces Expiration Of Hart-Scott-Rodino Waiting Period In Connection With Acquisition Of Valtech Cardio

HeartWare International, Inc. (Nasdaq: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure,...
Nov 2, 2015

IN.PACT Admiral Drug-Coated Balloon Cost-Effectiveness Study and Global Study Results of In-Stent Restenosis Population Highlighted in Late Breaking Clinical Trials at VIVA 2015

Health-Economic Analysis Demonstrates Medtronic IN.PACT Admiral Drug-Coated Balloon Is Cost-Effective Compared to Standard PTA; Global Study Data Demonstrates Strong Clinical Outcomes in Patients with In-Stent Restenosis

DUBLIN and LAS VEGAS - Nov. 2, 2015 - Medtronic plc (NYSE: MDT) adds to the robust data for its IN.PACT® Admiral® drug-coated balloon (DCB) with the presentation of both its formal...
Nov 2, 2015

Medtronic Unveils New Aortic and Peripheral Data from Two Late-Breaking Clinical Trials at VIVA 2015

Meeting Highlights New Two-Year Data with Valiant Thoracic Stent Graft in Type B Aortic Dissection and Nine-Month Comparison Data in Leading Treatments for Peripheral Iliac Artery Disease

DUBLIN and LAS VEGAS - Nov. 2, 2015 - Medtronic plc (NYSE: MDT) today announced new clinical data in interventional treatments for aortic and peripheral vascular diseases in a late-breaking trial...
Nov 2, 2015

REALITY Study to Evaluate Use of Directional Atherectomy and Drug Coated Balloon in Patients with Peripheral Arterial Disease

VIVA Physician Sponsored Study to Determine the Benefits of Debulking Plaque and Maximizing Luminal Gain Prior to Drug Coated Balloon Therapy

DUBLIN and LAS VEGAS - Nov. 2, 2015 - Medtronic plc (NYSE: MDT) announced today the initiation of the REALITY Study (DiRectional AthErectomy + Drug-coAted BaLloon to Treat Long, Calcified...
Oct 29, 2015

HeartWare International Reports Third Quarter 2015 Results

-- Total revenue of $65.2 million reflects completion of enrollment in destination therapy clinical trial and international currency weakness

HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure,...

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa